Remicade

Approved Uses

Remicade is used to treat various autoimmune and inflammatory conditions in adults and, in some cases, children. It is typically prescribed when other treatments have not been effective enough.

Digestive Conditions

• Crohn's Disease: Used for adults and children 6 years of age and older with moderate to severe active disease. It helps reduce symptoms and can help close fistulas (abnormal openings between the intestine and other organs or the skin).
• Ulcerative Colitis: Used for adults and children 6 years of age and older with moderate to severe active disease to help achieve and maintain remission.

Joint and Bone Conditions

• Rheumatoid Arthritis: Used in combination with methotrexate to reduce symptoms, improve physical function, and slow the progression of joint damage in adults with moderate to severe disease.
• Ankylosing Spondylitis: Used to reduce signs and symptoms in adults with this type of arthritis that primarily affects the spine.
• Psoriatic Arthritis: Used to reduce symptoms, improve physical function, and slow the progression of joint damage in adults with active disease.

Skin Conditions

• Plaque Psoriasis: Used for adults with chronic severe plaque psoriasis who are candidates for systemic therapy (medication that works throughout the body) or phototherapy (light treatment).

Mechanism of Action

Remicade (infliximab) belongs to a class of medications known as tumor necrosis factor (TNF) blockers. It is a monoclonal antibody, which is a type of protein designed to recognize and bind to a specific target in the body.

The primary target of Remicade is a protein called tumor necrosis factor-alpha (TNF-alpha). In a healthy body, TNF-alpha is produced by the immune system to help regulate inflammation. However, in people with certain autoimmune diseases, the body produces excessive amounts of this protein.

High levels of TNF-alpha lead to several issues, including:

• Persistent inflammation in various tissues, such as the joints, skin, or digestive tract.
• Damage to healthy organs and tissues.
• Symptoms like pain, swelling, and stiffness.

When Remicade is administered, it circulates in the bloodstream and attaches itself to TNF-alpha. By binding to this protein, Remicade prevents it from reaching the receptors on cells that would normally trigger an inflammatory response. This action helps to lower inflammation, manage symptoms, and potentially prevent further tissue damage caused by the overactive immune system.

Common Side Effects

Many people using Remicade experience mild side effects. These may include:

• Headache
• Nausea or stomach pain
• Sinus infections or sore throat
• Cough or runny nose
• Rash or itching

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention. These include:

• Serious infections: Increased risk of tuberculosis, fungal infections, and other bacterial or viral infections.
• Infusion reactions: Symptoms such as fever, chills, chest pain, shortness of breath, or changes in blood pressure occurring during or shortly after the treatment.
• Liver problems: Signs include yellowing of the skin or eyes (jaundice), dark brown urine, or right-sided stomach pain.
• Heart failure: New or worsening shortness of breath or swelling of the ankles or feet.
• Lupus-like syndrome: Joint pain or a rash on the cheeks or arms that worsens in the sun.
• Nervous system disorders: Numbness, tingling, or changes in vision.
• Skin changes: New or changing moles or skin lesions.

In rare cases, certain types of cancer, such as lymphoma, have been reported in patients using TNF blockers like Remicade. Patients should also be monitored for signs of new or worsening psoriasis.

Serious Infections

Remicade can lower the ability of the immune system to fight infections. Serious and sometimes fatal infections, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections, have occurred in patients using this medication. Testing for TB is typically required before starting treatment and throughout therapy. Treatment is usually withheld if a serious infection develops.

Risk of Cancer

Lymphoma and other malignancies have been reported in children and adolescents treated with TNF blockers. A rare and often fatal type of cancer called hepatosplenic T-cell lymphoma has occurred, primarily in adolescent and young adult males with Crohn's disease or ulcerative colitis who were also taking other immunosuppressants like azathioprine or 6-mercaptopurine.

Heart Failure

This medication may cause new or worsening heart failure. It is generally avoided or used with extreme caution in individuals with moderate to severe heart failure. Patients are monitored for symptoms such as shortness of breath, swelling of the ankles or feet, and sudden weight gain.

Liver and Blood Problems

Severe liver damage, including acute liver failure and hepatitis, has been reported. Signs of liver issues include yellowing of the skin or eyes, dark urine, and right-sided abdominal pain. Additionally, blood disorders such as low white blood cell or platelet counts may occur, which can increase the risk of bleeding or infection.

Neurological Effects

TNF blockers have been associated with the development or worsening of central nervous system demyelinating disorders, such as multiple sclerosis or Guillain-Barré syndrome. Individuals with a history of these conditions should discuss the risks with a healthcare provider.

Infusion and Hypersensitivity Reactions

Acute infusion reactions can occur during or shortly after the administration, potentially causing fever, chills, chest pain, or changes in blood pressure. Delayed hypersensitivity reactions, characterized by fever, rash, headache, and joint or muscle pain, may also occur three to twelve days after treatment.

Vaccinations

Live vaccines should not be administered while using Remicade. It is recommended that all pediatric patients be brought up to date with all vaccinations according to current guidelines before starting therapy.

Pregnancy

Research on the use of Remicade during pregnancy has not shown an increased risk of major birth defects. However, the medication is known to cross the placenta, particularly during the third trimester. This means the baby may be born with the medication in their system, which could affect their immune system's ability to fight infections.

If you received Remicade during pregnancy, it is important to inform your child's pediatrician. Infants exposed to this medication in the womb should generally not receive live vaccines (such as the rotavirus vaccine) for at least six months after birth, as their immune system may be temporarily suppressed.

Breastfeeding

Remicade passes into breast milk in very small amounts. While current evidence suggests that it is unlikely to cause harm to a nursing infant, you should discuss the risks and benefits with your healthcare provider before breastfeeding while using this medication.

Dosage Forms

Remicade is available in the following form:

• Powder for Injection: This is a sterile, preservative-free, lyophilized powder provided in a single-dose vial.

Administration Method

This medication is not taken by mouth or self-injected at home. Instead, it is prepared by a healthcare provider and given as an intravenous infusion. This process involves dripping the medicine slowly into a vein, usually in the arm, over a period of time in a clinical setting.

FDA Approval and Indications

Remicade (infliximab) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various autoimmune and inflammatory disorders. It is indicated for use in both adults and children for certain conditions, including:

• Crohn's disease (adults and children 6 years and older)
• Ulcerative colitis (adults and children 6 years and older)
• Rheumatoid arthritis (in combination with methotrexate)
• Ankylosing spondylitis
• Psoriatic arthritis
• Chronic severe plaque psoriasis

Boxed Warning

The FDA has issued a boxed warning for Remicade due to the risk of serious infections and malignancy. Because Remicade affects the immune system, it can lower the body's ability to fight infections. Reported serious infections include tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Patients must be tested for latent TB before starting treatment and monitored for active TB during therapy.

There is also an increased risk of lymphoma and other cancers in children and adolescent patients treated with TNF blockers like Remicade. Specifically, cases of hepatosplenic T-cell lymphoma, a rare and often fatal cancer, have occurred in young adults and children with inflammatory bowel disease who were also taking other immunosuppressive medications.

Regulatory Monitoring

The FDA requires healthcare providers to monitor patients closely for signs of infection or malignancy during and after treatment. Patients are advised to seek medical attention immediately if they develop symptoms such as fever, persistent cough, or unusual weight loss. The medication is administered via intravenous infusion, typically in a clinical setting where patients can be monitored for immediate infusion reactions.

The Infusion Process

Remicade is not available as a self-injection. It must be given through a needle placed into a vein, usually in the arm, by a doctor or nurse. This process is called an intravenous infusion and is performed in a hospital, clinic, or specialized infusion center.

Timing and Schedule

A standard infusion usually lasts about two hours. After the initial dose, the medication is typically given again at two weeks and six weeks. Following these three starting doses, maintenance infusions are usually scheduled every six or eight weeks, depending on the condition being treated.

Preparation and Monitoring

To help prevent infusion reactions, a healthcare provider may give other medications before the Remicade infusion starts, such as:

• Antihistamines
• Acetaminophen
• Corticosteroids

During the infusion and for a period of time afterward, medical staff will monitor for signs of a reaction, such as changes in blood pressure or heart rate. If a reaction occurs, the infusion may be slowed down or stopped.

Potential Infusion Reactions

Some patients experience side effects during or shortly after the infusion. It is important to notify a healthcare provider immediately if any of the following occur:

• Fever or chills
• Chest pain
• Shortness of breath
• Itching or hives
• Flushing or sweating
• Nausea or headache